GlaxoSmithKline
Europe, England, United Kingdom, London'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
Description
GlaxoSmithKline develops and markets products in the areas of pain relief, respiratory, digestive health, oral health, nutrition and skin.
Investor Profile
GlaxoSmithKline has made 27 investments, with 1 in the past 12 months and 48% as lead.
Stage Focus
- Series A (30%)
- Post Ipo Equity (19%)
- Series B (15%)
- Series C (11%)
- Series Unknown (11%)
- Series D (4%)
- Series F (4%)
- Corporate Round (4%)
- Grant (4%)
Country Focus
- United States (70%)
- United Kingdom (11%)
- Canada (7%)
- Switzerland (4%)
- Germany (4%)
- Denmark (4%)
Industry Focus
- Biotechnology
- Health Care
- Therapeutics
- Medical
- Pharmaceutical
- Biopharma
- Medical Device
- Life Science
- Genetics
- Product Research
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
